Arcellx announces its participation at td cowen's 6th annual oncology innovation summit and its investor event during eha2025

Redwood city, calif.--(business wire)--arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: td cowen's 6th annual oncology innovation summit tuesday, may 27, 2025 at 9:00 a.m. pt (virtual) management and physician presentation and discussion of immagine-1 pivotal study results during eha2025 friday, june 13, 2025 at.
ACLX Ratings Summary
ACLX Quant Ranking